

SEQUENCE LISTING

<110> Young, James F.
Johnson, Leslie S.
Huse, William D.
Wu, Herren
Watkins, Jeffry D.

<120> Ultra High Affinity Neutralizing Antibodies

<130> 469201-589

<140>
<141>

<150> 09/771,415
<151> 2001-01-26

<150> 60/178,426
<151> 2000-01-27

<160> 26

<170> PatentIn Ver. 2.1

<210> 1
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Mouse human
chimeric antibody light chain variable chain

<400> 1
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Gly Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
85 90 95
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> 2
 <211> 120
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Mouse human
 chimeric antibody heavy chain variable chain

<400> 2
 Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
 1 5 10 15
 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
 20 25 30
 Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
 35 40 45
 Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser
 50 55 60
 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
 65 70 75 80
 Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
 85 90 95
 Cys Ala Arg Ser Met Ile Thr Asn Trp Tyr Phe Asp Val Trp Gly Gln
 100 105 110
 Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> 3
 <211> 10
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Amino acid
 sequence of complementarity determining region L1
 of reference anti-RSV antibody

<400> 3
 Ser Ala Ser Ser Ser Val Gly Tyr Met His
 1 5 10

<210> 4
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Amino acid
 sequence of complementarity determining region L2
 of reference anti-RSV antibody

<400> 4
 Asp Thr Ser Lys Leu Ala Ser
 1 5

<210> 5
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Amino acid
 sequence of complementarity determining region L3
 of reference anti-RSV antibody

<400> 5
 Phe Gln Gly Ser Gly Tyr Pro Phe Thr
 1 5

<210> 6
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Amino acid
 sequence of complementarity determining region H1
 of reference anti-RSV antibody

<400> 6
 Thr Ser Gly Met Ser Val Gly
 1 5

<210> 7
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Amino acid
 sequence of complementarity determining region H2
 of reference anti-RSV antibody

<400> 7
 Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser Leu Lys Ser
 1 5 10 15

<210> 8
 <211> 10
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Amino acid
 sequence of complementarity determining region H3
 of reference anti-RSV antibody

<400> 8
 Ser Met Ile Thr Asn Trp Tyr Phe Asp Val
 1 5 10

<210> 9
 <211> 7
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Amino acid
 sequence present in high affinity complementarity
 determining regions of antibodies of the invention

<400> 9
 Thr Ala Gly Met Ser Val Gly
 1 5

<210> 10
 <211> 7
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Amino acid
 sequence present in high affinity complementarity
 determining regions of antibodies of the invention

<400> 10
 Thr Pro Gly Met Ser Val Gly
 1 5

<210> 11
 <211> 10
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Amino acid
 sequence present in high affinity complementarity
 determining regions of antibodies of the invention

<400> 11
Ser Met Ile Thr Asn Phe Tyr Phe Asp Val
1 5 10

<210> 12
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Amino acid
sequence present in high affinity complementarity
determining regions of antibodies of the invention

<400> 12
Asp Thr Phe Lys Leu Ala Ser
1 5

<210> 13
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Amino acid
sequence present in high affinity complementarity
determining regions of antibodies of the invention

<400> 13
Asp Thr Tyr Lys Leu Ala Ser
1 5

<210> 14
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Amino acid
sequence present in high affinity complementarity
determining regions of antibodies of the invention

<400> 14
Phe Gln Gly Ser Phe Tyr Pro Phe Thr
1 5

<210> 15
<211> 9
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Amino acid
sequence present in high affinity complementarity
determining regions of antibodies of the invention

<400> 15

Phe Gln Gly Ser Tyr Tyr Pro Phe Thr
1 5

<210> 16

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Amino acid
sequence present in high affinity complementarity
determining regions of antibodies of the invention

<400> 16

Phe Gln Gly Ser Trp Tyr Pro Phe Thr
1 5

<210> 17

<211> 106

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Amino acid
sequence of light chain variable region of clone 1
of Figure 3A

<400> 17

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Gly Tyr Met
20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45

Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80

Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Phe Tyr Pro Phe Thr
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys

100

105

<210> 18
 <211> 120
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Amino acid
 sequence of heavy chain variable region of clone 1
 of Figure 3B

<400> 18

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
 1 5 10 15

Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ala
 20 25 30

Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
 35 40 45

Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser
 50 55 60

Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
 65 70 75 80

Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
 85 90 95

Cys Ala Arg Ser Met Ile Thr Asn Phe Tyr Phe Asp Val Trp Gly Gln
 100 105 110

Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> 19
 <211> 106
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Amino acid
 sequence of light chain variable region of clone 2
 of Figure 4A

<400> 19

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Gly Tyr Met
 20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
 35 40 45
 Asp Thr Phe Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
 50 55 60
 Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
 65 70 75 80
 Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
 85 90 95
 Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 20

<211> 120

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Amino acid
sequence of heavy chain variable region of clone 2
of Figure 4B

<400> 20

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
 1 5 10 15
 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ala
 20 25 30
 Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
 35 40 45
 Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser
 50 55 60
 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
 65 70 75 80
 Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
 85 90 95
 Cys Ala Arg Ser Met Ile Thr Asn Phe Tyr Phe Asp Val Trp Gly Gln
 100 105 110
 Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> 21

<211> 106

<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Amino acid
sequence of light chain variable region of clone 3
of Figure 5A

<400> 21

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Gly Tyr Met
20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45

Asp Thr Phe Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80

Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Phe Tyr Pro Phe Thr
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> 22

<211> 120

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Amino acid
sequence of heavy chain variable region of clone 3
of Figure 5B

<400> 22

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15

Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Pro
20 25 30

Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45

Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val

65		70		75		80									
Val	Leu	Lys	Val	Thr	Asn	Met	Asp	Pro	Ala	Asp	Thr	Ala	Thr	Tyr	Tyr
			85						90					95	
Cys	Ala	Arg	Ser	Met	Ile	Thr	Asn	Phe	Tyr	Phe	Asp	Val	Trp	Gly	Gln
		100						105					110		
Gly	Thr	Thr	Val	Thr	Val	Ser	Ser								
		115					120								

<210> 23
 <211> 106
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Amino acid
 sequence of light chain variable region of clone
 22 of Figure 6A

<400> 23
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Gly Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45
Asp Thr Phe Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Phe Tyr Pro Phe Thr
85 90 95
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> 24
 <211> 120
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Amino acid
 sequence of heavy chain variable region of clone
 22 of Figure 6B

<400> 24
 Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
 1 5 10 15
 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ala
 20 25 30
 Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
 35 40 45
 Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser
 50 55 60
 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
 65 70 75 80
 Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
 85 90 95
 Cys Ala Arg Ser Met Ile Thr Asn Phe Tyr Phe Asp Val Trp Gly Gln
 100 105 110
 Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> 25
 <211> 106
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Amino acid
 sequence of light chain variable region of clone
 23 of Figure 7A

<400> 25
 Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Gly Tyr Met
 20 25 30
 His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
 35 40 45
 Asp Thr Phe Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
 50 55 60
 Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
 65 70 75 80
 Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Tyr Tyr Pro Phe Thr
 85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> 26

<211> 120

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Amino acid
sequence of heavy chain variable region of clone
23 of Figure 7B

<400> 26

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15

Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ala
20 25 30

Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45

Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80

Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
85 90 95

Cys Ala Arg Ser Met Ile Thr Asn Phe Tyr Phe Asp Val Trp Gly Gln
100 105 110

Gly Thr Thr Val Thr Val Ser Ser
115 120